



**CONTACT:** Robert Murphy  
The Storch-Murphy Group  
(908) 276-0777  
rmurphy@storchmurphy.com

**FOR IMMEDIATE RELEASE**

**TERUMO MEDICAL CORPORATION ANNOUNCES FDA 510K CLEARANCE OF THE K-PACK SURSHIELD™ HYPODERMIC NEEDLE WITH INTEGRATED PASSIVE SHARPS PROTECTION**

*New Package Design Allows Fully Automated Secondary Packaging Of Parenteral Medication Within Optimized Space Requirements Inside The Secondary Container*

SOMERSET, NJ (September 14, 2011)— Terumo Medical Corporation, a U.S.-based subsidiary of Terumo Corporation, today announced receipt of 510k clearance from the U.S. Food & Drug Administration to market the new K-Pack Surshield™ hypodermic needle featuring integrated, passive sharps protection for use with pre-filled syringes for intramuscular and subcutaneous pharmaceutical applications.

The K-Pack Surshield comes individually packaged and sterile in a rigid container with a tamper-evident and color-coded label. Initially, U.S. customers will have access to the K-Pack Surshield with Terumo's high-quality 25-gauge needle designed for minimal patient trauma. However, Terumo has already applied for 510k clearance of its smaller 27-gauge needle. The K-Pack Surshield 25-gauge needle has CE Mark approval for marketing outside the U.S., while the 27-gauge device is currently in the CE Marking approval process.

“Terumo’s innovative K-Pack Surshield offers exceptional performance and safety for the healthcare professional,” said Juichi (Jim) Takeuchi, President and CEO, Terumo Medical Corporation. “However, it is the truly unique packaging that distinguishes this device from all other competitive platforms. Our deeper understanding of industry needs allowed us the insight to specifically design the K-Pack Surshield so that our pharmaceutical customers can fully automate packaging processes for secondary packaging of parenteral medication with minimum space requirements of the secondary packaging.”

For more information on K-Pack Surshield™, please contact Reagan Broussard, Manager, Corporate Accounts, Global Pharmaceutical Solutions, Terumo Medical Corporation, at (214) 912-4218 or email [support@terumomedical.com](mailto:support@terumomedical.com).

- more -

**Terumo Medical Corporation**

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

**Terumo Corporation**

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with \$4 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

###

